Greater Phoenix bioscience alliances drive Castle Biosciences transformation

Greater Phoenix bioscience alliances drive Castle Biosciences transformation
Castle Biosciences cites Phoenix network

Castle Biosciences attributes its growth from a small startup to a diagnostics company to the support of the Greater Phoenix bioscience community.

Company co-founder and COO Kristen Oelschlager noted in an interview with In Business Phoenix that local research institutions and organizations such as AZBio played a pivotal role in shaping Castle Biosciences' trajectory. Their collaboration and resources have been instrumental in helping the company scale its operations and advance its diagnostics offerings.

Castle Biosciences reported Q2 2026 revenue of $103.5 million, driven by a 32 percent increase in core test volume over the same period in 2025. The company disclosed these results in its quarterly earnings release. The test volume growth reflects continued expansion of its diagnostics business.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.